A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy

Antonino Sottile, Cinzia Ortega, Alfredo Berruti, Monica Mangioni, Sara Saponaro, Alessandra Polo, Veronica Prati, Giovanni Muto, Massimo Aglietta, Filippo Montemurro

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

[-2]pro-prostate-specific antigen (2pPSA), a proform of PSA, is a new marker in patients at risk of prostate cancer. We explored the potential role of 2pPSA in the identification of patients with metastatic progression following radical prostatectomy for prostate cancer. Seventy-six patients with biochemical (PSA) recurrence following radical prostatectomy were studied retrospectively. Diagnostic imaging performed at the time of biochemical recurrence confirmed metastatic disease in 31 of the 76 patients. Serum samples were collected and stored at the time of imaging-confirmed metastatic progression or at the most recent procedure for patients with negative imaging. Median values of PSA, free PSA (fPSA), %fPSA, 2pPSA and prostate health index (PHI) were compared between metastatic and non-metastatic patients by the Mann-Whitney U test. The results of each test were then correlated with metastatic status by univariate and multivariate logistic regression analysis. PSA, fPSA, %fPSA, 2pPSA serum concentrations and PHI values were statistically significantly higher in patients with metastatic disease. Results of the multivariate analysis revealed that 2pPSA remained a statistically significant predictor of imaging-proven metastatic prostate cancer among patients with biochemical recurrence. At a cut-off value of 12.25 pg/ml, 2pPSA outperformed the other markers in terms of sensitivity and specificity (97 and 80%, respectively) with respect to imaging-confirmed metastatic progression. This is the first study suggesting that 2pPSA predicts diagnostic imaging-proven metastatic disease in previously resected prostate cancer patients with biochemical recurrence. Our results merit validation in a prospective study.

Original languageEnglish
Pages (from-to)819-824
Number of pages6
JournalOncology Letters
Volume3
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Serum
Prostatic Neoplasms
Recurrence
Diagnostic Imaging
Prostate
Health
Nonparametric Statistics
Multivariate Analysis
Logistic Models
Regression Analysis
Prospective Studies
Sensitivity and Specificity

Keywords

  • [-2]pro-prostate-specific antigen
  • Biochemical recurrence
  • Cancer metastasis
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. / Sottile, Antonino; Ortega, Cinzia; Berruti, Alfredo; Mangioni, Monica; Saponaro, Sara; Polo, Alessandra; Prati, Veronica; Muto, Giovanni; Aglietta, Massimo; Montemurro, Filippo.

In: Oncology Letters, Vol. 3, No. 4, 04.2012, p. 819-824.

Research output: Contribution to journalArticle

@article{da12e178ef2546f6ba5c9da7e9efe343,
title = "A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy",
abstract = "[-2]pro-prostate-specific antigen (2pPSA), a proform of PSA, is a new marker in patients at risk of prostate cancer. We explored the potential role of 2pPSA in the identification of patients with metastatic progression following radical prostatectomy for prostate cancer. Seventy-six patients with biochemical (PSA) recurrence following radical prostatectomy were studied retrospectively. Diagnostic imaging performed at the time of biochemical recurrence confirmed metastatic disease in 31 of the 76 patients. Serum samples were collected and stored at the time of imaging-confirmed metastatic progression or at the most recent procedure for patients with negative imaging. Median values of PSA, free PSA (fPSA), {\%}fPSA, 2pPSA and prostate health index (PHI) were compared between metastatic and non-metastatic patients by the Mann-Whitney U test. The results of each test were then correlated with metastatic status by univariate and multivariate logistic regression analysis. PSA, fPSA, {\%}fPSA, 2pPSA serum concentrations and PHI values were statistically significantly higher in patients with metastatic disease. Results of the multivariate analysis revealed that 2pPSA remained a statistically significant predictor of imaging-proven metastatic prostate cancer among patients with biochemical recurrence. At a cut-off value of 12.25 pg/ml, 2pPSA outperformed the other markers in terms of sensitivity and specificity (97 and 80{\%}, respectively) with respect to imaging-confirmed metastatic progression. This is the first study suggesting that 2pPSA predicts diagnostic imaging-proven metastatic disease in previously resected prostate cancer patients with biochemical recurrence. Our results merit validation in a prospective study.",
keywords = "[-2]pro-prostate-specific antigen, Biochemical recurrence, Cancer metastasis, Prostate cancer",
author = "Antonino Sottile and Cinzia Ortega and Alfredo Berruti and Monica Mangioni and Sara Saponaro and Alessandra Polo and Veronica Prati and Giovanni Muto and Massimo Aglietta and Filippo Montemurro",
year = "2012",
month = "4",
doi = "10.3892/ol.2012.570",
language = "English",
volume = "3",
pages = "819--824",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy

AU - Sottile, Antonino

AU - Ortega, Cinzia

AU - Berruti, Alfredo

AU - Mangioni, Monica

AU - Saponaro, Sara

AU - Polo, Alessandra

AU - Prati, Veronica

AU - Muto, Giovanni

AU - Aglietta, Massimo

AU - Montemurro, Filippo

PY - 2012/4

Y1 - 2012/4

N2 - [-2]pro-prostate-specific antigen (2pPSA), a proform of PSA, is a new marker in patients at risk of prostate cancer. We explored the potential role of 2pPSA in the identification of patients with metastatic progression following radical prostatectomy for prostate cancer. Seventy-six patients with biochemical (PSA) recurrence following radical prostatectomy were studied retrospectively. Diagnostic imaging performed at the time of biochemical recurrence confirmed metastatic disease in 31 of the 76 patients. Serum samples were collected and stored at the time of imaging-confirmed metastatic progression or at the most recent procedure for patients with negative imaging. Median values of PSA, free PSA (fPSA), %fPSA, 2pPSA and prostate health index (PHI) were compared between metastatic and non-metastatic patients by the Mann-Whitney U test. The results of each test were then correlated with metastatic status by univariate and multivariate logistic regression analysis. PSA, fPSA, %fPSA, 2pPSA serum concentrations and PHI values were statistically significantly higher in patients with metastatic disease. Results of the multivariate analysis revealed that 2pPSA remained a statistically significant predictor of imaging-proven metastatic prostate cancer among patients with biochemical recurrence. At a cut-off value of 12.25 pg/ml, 2pPSA outperformed the other markers in terms of sensitivity and specificity (97 and 80%, respectively) with respect to imaging-confirmed metastatic progression. This is the first study suggesting that 2pPSA predicts diagnostic imaging-proven metastatic disease in previously resected prostate cancer patients with biochemical recurrence. Our results merit validation in a prospective study.

AB - [-2]pro-prostate-specific antigen (2pPSA), a proform of PSA, is a new marker in patients at risk of prostate cancer. We explored the potential role of 2pPSA in the identification of patients with metastatic progression following radical prostatectomy for prostate cancer. Seventy-six patients with biochemical (PSA) recurrence following radical prostatectomy were studied retrospectively. Diagnostic imaging performed at the time of biochemical recurrence confirmed metastatic disease in 31 of the 76 patients. Serum samples were collected and stored at the time of imaging-confirmed metastatic progression or at the most recent procedure for patients with negative imaging. Median values of PSA, free PSA (fPSA), %fPSA, 2pPSA and prostate health index (PHI) were compared between metastatic and non-metastatic patients by the Mann-Whitney U test. The results of each test were then correlated with metastatic status by univariate and multivariate logistic regression analysis. PSA, fPSA, %fPSA, 2pPSA serum concentrations and PHI values were statistically significantly higher in patients with metastatic disease. Results of the multivariate analysis revealed that 2pPSA remained a statistically significant predictor of imaging-proven metastatic prostate cancer among patients with biochemical recurrence. At a cut-off value of 12.25 pg/ml, 2pPSA outperformed the other markers in terms of sensitivity and specificity (97 and 80%, respectively) with respect to imaging-confirmed metastatic progression. This is the first study suggesting that 2pPSA predicts diagnostic imaging-proven metastatic disease in previously resected prostate cancer patients with biochemical recurrence. Our results merit validation in a prospective study.

KW - [-2]pro-prostate-specific antigen

KW - Biochemical recurrence

KW - Cancer metastasis

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84856829087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856829087&partnerID=8YFLogxK

U2 - 10.3892/ol.2012.570

DO - 10.3892/ol.2012.570

M3 - Article

AN - SCOPUS:84856829087

VL - 3

SP - 819

EP - 824

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 4

ER -